Mark Bodmer

2.7k total citations
31 papers, 2.0k citations indexed

About

Mark Bodmer is a scholar working on Molecular Biology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark Bodmer has authored 31 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Immunology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark Bodmer's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Immune Response and Inflammation (6 papers) and Sepsis Diagnosis and Treatment (4 papers). Mark Bodmer is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Immune Response and Inflammation (6 papers) and Sepsis Diagnosis and Treatment (4 papers). Mark Bodmer collaborates with scholars based in United States, United Kingdom and France. Mark Bodmer's co-authors include Michael Ashburner, John R. Adair, Sarojani Angal, Alan S. Cross, Jerald Sadoff, Sue Stephens, David J. King, Steven M. Opal, Jean Palardy and Andrew Nesbitt and has published in prestigious journals such as Nature, The Lancet and Nucleic Acids Research.

In The Last Decade

Mark Bodmer

31 papers receiving 1.9k citations

Peers

Countries citing papers authored by Mark Bodmer

Since Specialization

Citations

This map shows the geographic impact of Mark Bodmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Bodmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Bodmer more than expected).

Fields of papers citing papers by Mark Bodmer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Bodmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Bodmer. The network helps show where Mark Bodmer may publish in the future.

Co-authorship network of co-authors of Mark Bodmer

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Bodmer. A scholar is included among the top collaborators of Mark Bodmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Bodmer. Mark Bodmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis 2024 ·Frontiers in Medicine ·Benjamin D. Ehst, Bruce Strober, Andrew Blauvelt, (unknown), (unknown), Nancy J. Carpenter, Mark Bodmer, (unknown)	3
2	Clinical translation of anti-inflammatory effects of Prevotella histicola in Th1, Th2, and Th17 inflammation 2023 ·Frontiers in Medicine ·Andrea Itano, (unknown), Kritika Ramani, Golbarg Mehraei, Nancy J. Carpenter, (unknown), (unknown), Matthijs Moerland, Erin B. Troy, (unknown), (unknown), Stuart Abel, (unknown), Mark Bodmer	11
3	Harnessing the small intestinal axis to resolve systemic inflammation 2022 ·Frontiers in Immunology ·Mark Bodmer, Andrea Itano, Iain B. McInnes	6
4	16003 Orally administered EDP1815, a monoclonal strain of Prevotella histicola, has potent systemic anti-inflammatory effects 2020 ·Journal of the American Academy of Dermatology ·Andrea Itano, (unknown), Kritika Ramani, (unknown), Holly Ponichtera, Tanmoy Ganguly, Mark Bodmer	4
5	Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient 2007 ·Nephrology Dialysis Transplantation ·Mark Bodmer, Patrizia Amico, M. J. Mihatsch, Manuel Haschke, Oliver Kummer, S. Krähenbühl, Michael Mayr	33
6	Inhibition of Pulmonary Eosinophilia and Hyperreactivity by Antibodies to lnterleukin-5 1995 ·International Archives of Allergy and Immunology ·Robert W. Egan, (unknown), Chuan‐Chu Chou, Spencer Emtage, (unknown), Ted T. Kung, Peter Mauser, Nicholas Murgolo, Mark Bodmer	58
7	A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody 1993 ·Molecular Immunology ·Sarojani Angal, David J. King, Mark Bodmer, Alison Turner, (unknown), Gerald D. Roberts, R. Barbara Pedley, John R. Adair	187
8	Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis 1993 ·Critical Care Medicine ·Charles J. Fisher, Steven M. Opal, Jean-François Dhainaut, Sue Stephens, Janice L. Zimmerman, Peter Nightingale, (unknown), Roland M.H. Schein, Edward A. Panacek, Jean‐Louis Vincent, Garrett E. Foulke, Edward Warren, (unknown), Gilbert Park, Mark Bodmer, Jonathan Cohen, (unknown), Alan S. Cross, Jerald Sadoff	325
9	Preclinical review of anti-tumor necrosis factor monoclonal antibodies 1993 ·Critical Care Medicine ·Mark Bodmer, Michael A. Fournel, Lerner B. Hinshaw	22
10	The Efficacy of Combination Immunotherapy in Experimental Pseudomonas Sepsis 1993 ·The Journal of Infectious Diseases ·Alan S. Cross, Steven M. Opal, Jean Palardy, Mark Bodmer, Jerald Sadoff	45
11	Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression 1992 ·The Journal of Immunology ·E. Steve Woodle, J. Richard Thistlethwaite, Linda K. Jolliffe, Robert A. Zivin, (unknown), John R. Adair, Mark Bodmer, D. S. Athwal, Maria‐Luisa Alegre, Jeffrey A. Bluestone	52
12	Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis. 1991 ·Journal of Clinical Investigation ·Steven M. Opal, Alan S. Cross, Jerald Sadoff, H H Collins, N M Kelly, (unknown), Jean Palardy, Mark Bodmer	47
13	Generation and characterization of a recombinant/chimeric B72.3 (human gamma 1). 1991 ·PubMed ·(unknown), S. V. S. Kashmiri, David Colcher, F. James Primus, Patricia Horan Hand, Mario Roselli, (unknown), Geoffrey Yarranton, Mark Bodmer, Nigel Whittle	29
14	Monoclonal antibody to TN F in severe septic shock 1990 ·The Lancet ·Andrew Exley, J. Cohen, Wim A. Buurman, Robert L. Owen, (unknown), G C Hanson, (unknown), Mark Bodmer, Sue Stephens, Anna Riddell, Melissa J. Perry	150
15	Efficacy of a Monoclonal Antibody Directed against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with Pseudomonas aeruginosa 1990 ·The Journal of Infectious Diseases ·S M Opal, Alan S. Cross, N M Kelly, Jerald Sadoff, Mark Bodmer, Jean Palardy, (unknown)	88
16	Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. 1989 ·PubMed ·David Colcher, Diane E. Milenic, M Roselli, Andrew Raubitschek, G. T. Yarranton, Daniel Griffiths-King, John R. Adair, Nigel Whittle, Mark Bodmer, J Schlom	95
17	Expression in COS cells of a mouse—human chimaeric B72.3 antibody 1987 ·Protein Engineering Design and Selection ·Nigel Whittle, John R. Adair, Chris J. Lloyd, (unknown), Joan Devine, Jeffrey Schlom, Andrew Raubitschek, David Colcher, Mark Bodmer	80
18	Molecular cloning and nucleotide sequence of rat lingual lipase cDNA 1985 ·Nucleic Acids Research ·Andrew Docherty, Mark Bodmer, Sarojani Angal, R. Verger, C. Rivière, Peter A. Lowe, A. Bruce Lyons, J.S. Emtage, Timothy Harris	93
19	Conservation and change in the DNA sequences coding for alcohol dehydrogenase in sibling species of Drosophila 1984 ·Nature ·Mark Bodmer, Michael Ashburner	155
20	On the evolutionary relationships of Drosophila melanogaster 1983 ·Developmental Genetics ·Michael Ashburner, Mark Bodmer, Françoise Lemeunier	69

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact